IRIS
GIORGIO, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.862
AS - Asia 3.750
EU - Europa 3.505
SA - Sud America 487
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 187
Totale 14.035
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.726
SG - Singapore 1.223
IT - Italia 1.097
CN - Cina 1.028
VN - Vietnam 635
FI - Finlandia 456
IE - Irlanda 427
DE - Germania 413
BR - Brasile 385
SE - Svezia 365
HK - Hong Kong 238
FR - Francia 164
ZA - Sudafrica 154
IN - India 150
BD - Bangladesh 128
GB - Regno Unito 120
NL - Olanda 97
TR - Turchia 94
UA - Ucraina 78
RU - Federazione Russa 75
CA - Canada 64
BE - Belgio 52
AR - Argentina 43
CI - Costa d'Avorio 43
MX - Messico 40
JP - Giappone 32
ID - Indonesia 31
AT - Austria 28
IQ - Iraq 26
KR - Corea 25
ES - Italia 23
CZ - Repubblica Ceca 21
PK - Pakistan 20
PL - Polonia 20
TH - Thailandia 20
PH - Filippine 19
EC - Ecuador 14
JO - Giordania 13
VE - Venezuela 13
RO - Romania 12
LT - Lituania 11
SA - Arabia Saudita 11
CO - Colombia 9
EG - Egitto 9
JM - Giamaica 8
MA - Marocco 8
AL - Albania 7
CH - Svizzera 7
CL - Cile 7
HU - Ungheria 7
TN - Tunisia 7
UZ - Uzbekistan 7
KE - Kenya 6
KG - Kirghizistan 6
MY - Malesia 6
PY - Paraguay 6
BO - Bolivia 5
ET - Etiopia 5
HN - Honduras 5
LB - Libano 5
TW - Taiwan 5
PA - Panama 4
PE - Perù 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
HR - Croazia 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
SV - El Salvador 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CG - Congo 1
CM - Camerun 1
GA - Gabon 1
GF - Guiana Francese 1
Totale 13.843
Salva come PNG Salva come JPEG
Città #
Dallas 1.624
Singapore 664
Ashburn 507
Dublin 427
San Jose 426
Chandler 393
Parma 356
Santa Clara 290
Ann Arbor 282
Beijing 233
Hong Kong 219
Ho Chi Minh City 194
Munich 179
Boardman 174
Johannesburg 149
Council Bluffs 144
Dearborn 143
Hanoi 143
Los Angeles 110
New York 109
Helsinki 105
Shanghai 98
Jacksonville 87
Nanjing 76
Hefei 75
Izmir 71
Lauterbourg 68
Princeton 60
Bremen 59
Bologna 56
Wilmington 55
Milan 46
Abidjan 43
Chicago 43
Brussels 41
São Paulo 41
Columbus 37
Buffalo 35
Shenyang 31
Frankfurt am Main 30
London 30
San Mateo 30
Haiphong 29
Moscow 28
Bangalore 27
Guangzhou 27
Turku 27
Kunming 26
Da Nang 23
Rome 23
Toronto 23
Hillsboro 22
Modena 22
Tokyo 22
Brescia 21
Orem 21
Jakarta 20
Vienna 20
Jinan 19
Lubbock 19
Seoul 19
Nanchang 18
Nuremberg 18
Seattle 18
Des Moines 17
Düsseldorf 17
Fremont 17
Hebei 17
Houston 17
Montreal 17
The Dalles 17
Rio de Janeiro 16
Changsha 15
Grafing 15
Mexico City 15
Reggio Emilia 15
Bengaluru 14
Jiaxing 14
Woodbridge 14
Hangzhou 13
Tianjin 13
Belo Horizonte 12
Brooklyn 12
Dalmine 12
Denver 12
Naples 12
Amman 11
Amsterdam 11
Ankara 11
Boston 11
Brno 11
Chennai 11
Münster 11
Phoenix 11
Piacenza 11
Warsaw 11
Atlanta 10
Bangkok 10
Biên Hòa 10
Concesio 10
Totale 8.948
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.717
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 302
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 261
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 255
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 254
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 244
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 228
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 223
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 221
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 221
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 220
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 215
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 214
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 207
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 204
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 199
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 191
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 189
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 187
Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach 186
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 182
Enhanced photosensitizing properties of protein bound curcumin 181
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 179
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 178
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 177
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 175
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 174
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 173
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 170
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 167
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 165
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 165
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 165
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 162
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 162
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 160
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 160
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 160
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 159
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 157
Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth 153
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 153
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 152
Structure activity relationship of new EphA2 ligands 152
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 152
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 151
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 151
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 150
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 147
Discovery of natural extracts interfering with EphA2-ephrinA1 system 146
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 144
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 142
Target-hopping: a useful approach to identify novel Eph receptor antagonists 141
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 141
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 139
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 138
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 137
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 129
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 128
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 127
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 127
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 126
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 125
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept 122
Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. 121
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 117
Therapeutic perspectives of Eph–ephrin system modulation 114
Drug discovery: In silico dry data can bypass biological wet data? 110
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 106
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 105
UNIPR1331: SMALL EPH/EPHRIN ANTAGONIST BENEFICIAL IN INTESTINAL INFLAMMATION BY INTERFERING WITH TYPE-B SIGNALLING 105
Ephrin or not? Six tough questions on Eph targeting 101
Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives 95
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 91
Targeting Eph/ephrin system in cancer therapy 87
Dual targeting of EphAs and KDR axis hampers VEGF-induced angiogenesis and glioma stem cell replication 78
Protection by Eph/ephrin antagonists against TNBS-induced colitis: effects of the route of administration 74
Target validation of natural compounds: Perillaldehyde case study 38
Ricerca e caratterizzazione di ligandi per efrine chinasi coinvolte nei processi tumorali 11
Totale 14.035
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.257
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.257
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 23 27 108 36 27 45 44 36 40 18 111
2022/20231.650 161 172 77 133 185 175 42 89 505 27 56 28
2023/2024693 44 41 36 35 47 129 67 53 27 47 75 92
2024/20252.333 98 115 132 117 251 243 176 149 296 200 204 352
2025/20266.273 436 714 1.592 426 642 282 484 180 672 408 256 181
2026/2027312 171 141 0 0 0 0 0 0 0 0 0 0
Totale 14.035